Top Page
Singular Health Group Ltd
(Sydney:SHG)
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Singular Health Group Ltd Business Overview & Revenue Model
Singular Health Group Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 90.83K | 616.14K | 54.03K | 193.64K | 103.86K |
| Gross Profit | -2.67M | -3.58M | -2.11M | -1.62M | -669.39K |
| EBITDA | -2.89M | -4.52M | -5.72M | -2.90M | -637.00K |
| Net Income | -4.92M | -5.39M | -5.99M | -4.46M | -707.59K |
Balance Sheet | |||||
| Total Assets | 2.35M | 3.00M | 2.14M | 5.43M | 668.27K |
| Cash, Cash Equivalents and Short-Term Investments | 1.45M | 691.51K | 1.14M | 4.14M | 130.55K |
| Total Debt | 218.45K | 2.51M | 85.66K | 147.59K | 745.94K |
| Total Liabilities | 909.59K | 2.94M | 391.50K | 345.10K | 881.86K |
| Stockholders Equity | 1.44M | 61.89K | 1.75M | 5.08M | -213.59K |
Cash Flow | |||||
| Free Cash Flow | -2.51M | -2.49M | -2.92M | -2.22M | -807.48K |
| Operating Cash Flow | -2.44M | -2.46M | -2.91M | -1.91M | -548.17K |
| Investing Cash Flow | -3.56K | -635.21K | -17.12K | -610.57K | -259.31K |
| Financing Cash Flow | 3.21M | 2.65M | -69.25K | 6.52M | 950.69K |
Singular Health Group Ltd Technical Analysis
Singular Health Group Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$49.40M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
55 Neutral | AU$73.68M | ― | -457.46% | ― | 21.93% | 10.34% | |
53 Neutral | AU$161.15M | ― | -5.63% | ― | -11.96% | 7.50% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
52 Neutral | AU$75.55M | ― | -11.80% | ― | 14.56% | 13.36% | |
48 Neutral | AU$93.52M | ― | ― | ― | ― | ||
| ― | $66.76M | ― | -9.88% | ― | ― | ― |
Singular Health Group Ltd Corporate Events
Singular Health Group Ltd has announced the cessation of 300,000 performance rights due to the conditions for these rights not being met or becoming incapable of being satisfied. This cessation of securities may impact the company’s capital structure and could influence investor perception regarding the company’s performance and strategic direction.
Singular Health Group Ltd announced a proposed issue of 109,333 fully paid ordinary securities, with the issuance date set for January 5, 2026. This move is part of the company’s strategy to strengthen its financial position and support its ongoing operations, potentially impacting its market presence and stakeholder interests.
Singular Health Group Ltd has announced the quotation of 1,575,182 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of the company’s strategy to leverage convertible securities, potentially impacting its financial flexibility and market presence.
Singular Health Group Ltd has announced the quotation of 22,428,572 ordinary fully paid securities on the ASX, effective June 26, 2025. This move is part of previously announced transactions and signifies a strategic step in enhancing the company’s market presence and liquidity, potentially impacting its operational capabilities and investor engagement.
Singular Health Group has announced a live investor briefing to discuss a recent USD$1.3 million contract with Provider Network Solutions. This contract is expected to enhance Singular Health’s operations and industry positioning by expanding their reach and capabilities in medical imaging solutions. The briefing will provide insights into the company’s strategic direction and potential implications for stakeholders.
Singular Health Group Ltd has released a presentation outlining its current operations and investment risks. The company emphasizes that investing in its shares is highly speculative and high risk due to its startup nature. The presentation is informational and not an offer for securities, highlighting the need for prospective investors to conduct their own due diligence.
Singular Health Group Ltd has announced a proposed issue of securities, including 10 million unlisted options and over 22 million ordinary fully paid shares. This move is aimed at raising capital, which could potentially enhance the company’s operational capabilities and strengthen its position in the healthcare technology market.
Singular Health Group Ltd has signed a USD$1.3 million contract with Provider Network Solutions (PNS) to implement its 3DICOM technology within PNS’s network in Puerto Rico, Florida, and Texas. This agreement marks the first step towards a potential large-scale national deployment across the United States, addressing challenges such as unnecessary duplicate imaging and delays in disease detection. The contract includes the deployment of 1,000 3DICOM licenses and the development of an AI model marketplace and image repository. Additionally, Singular Health has completed an AUD$8 million capital raising to support the national rollout and further product development, with strong backing from institutional investors.
Singular Health Group Limited (ASX: SHG) has announced a trading halt on its securities pending a significant announcement related to a capital raising and a material commercial contract. The halt is expected to last until the commencement of normal trading on 19 June 2025 or until the company releases the anticipated announcement. This move suggests potential strategic developments that could impact SHG’s market position and stakeholder interests.
Singular Health Group Ltd has announced a change in the director’s interest, with Denning Chong acquiring 2,000,000 ordinary fully paid shares. This acquisition was made through the conversion of vested performance rights, previously issued under the company’s employee incentive plan. The announcement reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Singular Health Group Ltd has successfully completed a placement with Marin and Sons, issuing 4,831,250 new shares to raise $773,000. Additionally, the company raised funds through the exercise of options and issued shares under its employee incentive plan, reflecting a strategic effort to strengthen its financial position and reward contributors. This capital raising supports Singular Health’s mission to enhance its medical technology offerings and maintain its industry positioning, potentially benefiting stakeholders through improved operational capabilities.
Singular Health Group Ltd has announced the application for quotation of 4,927,728 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and liquidity. The issuance of these securities follows the exercise of options or conversion of other convertible securities, indicating an active engagement in capital market activities.
Singular Health Group Ltd has issued 844,985 fully paid ordinary shares following the exercise of unlisted options, raising $86,988.50. This move reflects the company’s ongoing compliance with the Corporations Act and its strategic efforts to enhance its financial position, potentially impacting its market operations and stakeholder interests.
Singular Health Group Ltd has announced the quotation of 844,985 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move follows the exercise of options or conversion of other convertible securities, reflecting the company’s ongoing financial activities and potential growth strategy. The announcement signifies an expansion in the company’s market presence and could have implications for its stakeholders by potentially increasing liquidity and shareholder value.